Merrimack Pharmaceuticals Inc financial data

Symbol
MACK on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.26K % -63.6%
Debt-to-equity 8.63 % +190%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.5M shares +1.94%
Common Stock, Shares, Outstanding 14.5M shares +1.94%
Entity Public Float 130M USD 0%
Common Stock, Value, Issued 1.35M USD +0.15%
Weighted Average Number of Shares Outstanding, Basic 14.5M shares +1.4%
Weighted Average Number of Shares Outstanding, Diluted 14.5M shares +1.4%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 2.26M USD +3.48%
Operating Income (Loss) -2.26M USD -10.5%
Nonoperating Income (Expense) 925K USD +32.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.17M USD +24.1%
Income Tax Expense (Benefit) 12K USD +300%
Earnings Per Share, Basic 13.9 USD/shares
Earnings Per Share, Diluted 13.9 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 234M USD +1107%
Cash, Cash Equivalents, and Short-term Investments 244M USD +1158%
Assets, Current 244M USD +1145%
Other Assets, Noncurrent 3K USD -57.1%
Assets 244M USD +1144%
Accounts Payable, Current 168K USD +88.8%
Accrued Liabilities, Current 161K USD +17.5%
Liabilities, Current 22.7M USD +4797%
Liabilities 22.7M USD +4797%
Retained Earnings (Accumulated Deficit) -347M USD +36.6%
Stockholders' Equity Attributable to Parent 222M USD +1056%
Liabilities and Equity 244M USD +1144%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.31M USD -269%
Net Cash Provided by (Used in) Financing Activities 1.49M USD +730%
Net Cash Provided by (Used in) Investing Activities 228M USD +163929%
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 14.5M shares +1.94%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 228M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 234M USD +1107%
Deferred Tax Assets, Valuation Allowance 250M USD +0.11%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 250M USD +0.11%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 200M USD
Deferred Tax Assets, Operating Loss Carryforwards 65.2M USD +1.65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 200K USD +100%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%